TheraVet (ALVET) Stock Overview

TheraVet SA, a veterinary biotechnology company, provides osteoarticular treatments for animals in Belgium, France, Switzerland, the United Kingdom, and the United States. The company primarily provides products for osteoarthritis, ligament and tendon injuries, and bone surgery in cats, dogs, and horses. It offers BIOCERA-VET, an injectable self-hardening phosphocalcic bone void filler for osteointegration, osteoinduction, and bone remodeling properties; and VISCO-VET, an injectable visco-regenerative gel based on hyaluronic acid, species specific plasma, and an active pharmaceutical component. The company also provides various products, such as BIOCERA-VET bone surgery RTU, a ready-to-use highly injectable self-hardening calcium-phosphate cement; BIOCERA-VET smartgraft, a naturally osteoconductive bone graft; BIOCERA-VET granules, an affordable biocompatible calcium-phosphate bone substitute; and BIOCERA-VET osteosarcoma RTU, a ready-to-use highly injectable calcium-phosphate bone substitute for cementoplasty. TheraVet SA was incorporated in 2017 and is based in Gosselies, Belgium.